Piper Sandler Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $7
Piper Sandler analyst Yasmeen Rahimi maintains $Aligos Therapeutics(ALGS.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 35.1
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.
Express News | Aligos Therapeutics Receives Nasdaq Notice Of Delisting Or Non-Compliance With Listing Standards
Express News | Aligos Therapeutics Inc - on May 29, Received Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard From Nasdaq
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr.
Express News | Aligos Therapeutics Inc - Topline Data Now Projected in Early Q4 2024
Express News | Aligos Therapeutics Announces the Completion of Enrollment in the Alg-055009 Phase 2a Herald Study for the Treatment of Mash
Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)
Aligos Therapeutics Announces Chief Medical Officer Resignation
Why Investors Shouldn't Be Surprised By Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 26% Share Price Plunge
The Aligos Therapeutics, Inc. (NASDAQ:ALGS) share price has softened a substantial 26% over the previous 30 days, handing back much of the gains the stock has made lately. The drop over the last 30
Aligos Therapeutics Reports Q1 Results
Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)
Aligos Therapeutics Q1 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $986.000K Down From $2.723M YoY
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 58.49 percent increase over losses o
Aligos Therapeutics | 10-Q: Quarterly report
Express News | Aligos Therapeutics Inc: Continue to Believe Our Cash Balance Provides Sufficient Cash to Fund Planned Operations Through End of 2025
Express News | Aligos Therapeutics Q1 Pretax Profit USD -34.839 Million
Express News | Aligos Therapeutics Q1 Income From Operations USD -22.046 Million
Express News | Aligos Therapeutics Q1 Net Income USD -34.863 Million
Press Release: Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "A
Aligos Therapeutics 1Q Loss/Shr 22c >ALGS
Aligos Therapeutics 1Q Loss/Shr 22c >ALGS
No Data